<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Identification Functional Characterisation of <br /> CRK12:CYC9, Novel Cyclin-Dependent Kinase (CDK)- <br /> Cyclin Complex Trypanosoma brucei <br /> Se&#194;&#180;verine Monnerat1, Cristina I. Almeida Costa2,4, Andrea C. Forkert1, Corinna Benz4&#194;&#164;, Alana Hamilton1, <br /> Laurence Tetley3, Richard Burchmore4, Carlos Novo2, Jeremy C. Mottram1*, Tansy C. Hammarton4* <br /> 1 Wellcome Trust Centre Molecular Parasitology, Institute Infection, Immunity Inflammation, University Glasgow, Glasgow, United Kingdom, 2 Instituto de <br /> Higiene e Medicina Tropical, Universidade Nova Lisboa, Lisbon, Portugal, 3 School Life Sciences, University Glasgow, Glasgow, United Kingdom, 4 Institute of <br /> Infection, Immunity Inflammation, University Glasgow, Glasgow, United Kingdom <br />  <br />  <br />  <br />      <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br />      The protozoan parasite, Trypanosoma brucei, spread tsetse fly causes trypanosomiasis humans animals. <br />      Both life cycle cell cycle parasite complex. Trypanosomes cdc2-related kinases (CRKs) ten <br />      cyclins, unusually large number single celled organism. <span id='am-3' about='protege:TO' typeof='owl:Thing'>To</span> date, relatively little known function many <br />      CRKs cyclins, CRK3 previously shown cyclin-dependent vivo. Here report the <br />      identification previously uncharacterised CRK:cyclin complex CRK12 putative transcriptional cyclin, <br />      CYC9. CRK12:CYC9 interact form active protein kinase complex procyclic bloodstream T. brucei. Both CRK12 and <br />      CYC9 essential proliferation bloodstream trypanosomes vitro, CRK12 essential for <br />      <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-6' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-56' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span>survival</span> T. brucei mouse model, providing genetic validation CRK12:CYC9 novel drug target for <br />      trypanosomiasis. Further, functional characterisation CRK12 CYC9 using <span id='am-394' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-395' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-396' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-397' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-398' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-399' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-400' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-401' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-402' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-403' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-404' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-405' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-406' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-407' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-408' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-409' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-410' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-411' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-412' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-413' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-414' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-415' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-416' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-417' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-418' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-419' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-420' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-421' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-422' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-423' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-424' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-425' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-426' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-427' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-428' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-429' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-430' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-431' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-432' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-433' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-434' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-435' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-436' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-437' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-438' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-439' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-440' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-441' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-442' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-443' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-444' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-445' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-446' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-447' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-448' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-449' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-450' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-451' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-452' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-453' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-454' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-455' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-456' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-457' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-458' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-459' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-460' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-461' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-462' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-463' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-464' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-465' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-466' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-467' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-468' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-469' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-470' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-471' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span>RNA interference</span> reveals roles these <br />      proteins endocytosis cytokinesis, respectively. <br />  <br />   Citation: Monnerat S, Almeida Costa CI, Forkert AC, Benz C, Hamilton A, et al. (2013) Identification Functional Characterisation CRK12:CYC9, Novel Cyclin- <br />   Dependent Kinase (CDK)-Cyclin Complex Trypanosoma brucei. PLoS ONE 8(6): e67327. doi:10.1371/journal.pone.0067327 <br />   Editor: Dan Zilberstein, Technion-Israel Institute Technology Haifa 32000 Israel., Israel <br />   Received June 18, 2012; Accepted May 20, 2013; Published June 21, 2013 <br />   Copyright: &#195;&#376; 2013 Monnerat et al. This open-access article distributed terms Creative Commons Attribution License, permits <br />   unrestricted use, distribution, reproduction medium, provided original author source credited. <br />   Funding: This work funded grants Wellcome Trust (to JCM TCH; reference number 070231), Swiss National Foundation (to SM JCM; <br />   reference number PBLA33-103364), MRC (Career Development fellowship reference number G120/1001 New Investigator Research Grant, reference <br />   number GO900239, TCH), RCUK (Academic fellowship reference number GR/T28003/01 TCH) Fundac&#194;&#184;a&#203;&#339;o para Cie&#203;&#8224;ancia e Tecnologia, Portugal (to <br />   CC: PhD Grant reference number SFRH/BD/40223/2007; CN: Project Development Grant reference number PTDC/CVT/098183/2008). The Wellcome Trust <br />   Centre Molecular Parasitology supported core funding Wellcome Trust [085349/Z/08/Z]. The funders role study design, data collection <br />   analysis, decision publish, preparation manuscript. <br />   Competing Interests: The authors declared competing interests exist. <br />   * E-mail: Jeremy.Mottram@glasgow.ac.uk (JCM); Tansy.Hammarton@glasgow.ac.uk (TCH) <br />   &#194;&#164; Current address: Institute Parasitology, Biology Centre Faculty Sciences, University South Bohemia, C&#203;&#8225;eske&#194;&#180; Bude&#203;&#8225;jovice, Czech Republic <br />  <br />  <br />  <br /> Introduction                                                                            cell cycle. Similarly, cyclins bind CDK. <br />                                                                                         Budding yeast express just major cell cycle CDK, CDC28, <br />    In eukaryotes, cyclin-dependent kinases (CDKs) funda-                         binds different cyclins promote successive cell cycle <br /> mental importance cell cycle progression [1&#226;&#8364;&#8220;3] play                        transitions [2]. On hand, 20 CDKs numerous <br /> essential roles regulating gene expression [4&#226;&#8364;&#8220;7], autophagy [8]                      cyclins identified mammalian cells, able to <br /> and neuronal function [9] key roles responding                         compensate absence [1]. <br /> stresses [10,11]. CDKs proline-directed serine-threonine                                The protozoan parasite, Trypanosoma brucei, causative agent <br /> kinases activated binding cyclin partner                           African trypanosomiasis humans animals. Its digenetic <br /> protein highly conserved PSTAIRE helix CDK                            life cycle, split mammalian host tsetse fly, is <br /> [12,13]. Since cyclins regulating cell cycle CDKs                       characterised multiple differentiation events yield series <br /> constitutively expressed, instead transcribed degraded                      life cycle stages, differ respect morphology, <br /> at specific points cell cycle, cyclin binding provides                     cell structure, surface coat biochemistry. Cell cycle control <br /> cell cycle-dependent mode CDK activation. In contrast,                               differs life cycle stages [20]. Only life cycle <br /> transcriptional cyclins expressed constant levels                           stages, procyclic form tsetse midgut, long <br /> throughout cell cycle [14&#226;&#8364;&#8220;16] neuronal CDK, CDK5,                           slender trypomastigote mammalian bloodstream, are <br /> is activated binding proteins p35 p39,                       proliferative, mesocyclic metacyclic <br /> have sequence similarity cyclins, adopt                       trypomastigotes tsetse fly short stumpy bloodstream <br /> cyclin-like fold [17&#226;&#8364;&#8220;19]. Cyclins activate CDKs,                      form cell cycle arrested. Eleven cdc2-related kinases (CRK1-4 <br /> determine substrate specificity and/or localisation CDK.                     CRK6-12) cyclins (CYC2-11) identified in <br /> A CDK bind cyclin cell cycle,                           T. brucei [20,21]. To date, functions assigned a <br /> and targeted different substrates different phases                 putative regulators, cases, depletion the <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                          1                                  June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                          Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br /> regulators RNA interference (RNAi) resulted                using William Pearson&#226;&#8364;&#8482;s LALIGN software available http:// <br /> detectable <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-85' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-86' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-94' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-102' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-113' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-129' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-130' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-134' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-157' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span>phenotype</span> [22,23]. While suggest              www.ch.embnet.org/software/LALIGN_form.html using Vec- <br /> CRKs cyclins non-essential proliferation culture          torNTi AlignX software (Invitrogen). Cyclin (CD00043 (cyclin <br /> that functional redundancy exists them, ruled          superfamily) and/or COG5024 (cyclin-like superfamily CCL1 <br /> out small protein remaining following RNAi               (TIGR00569)) kinase (PKc_like superfamily) domains were <br /> knockdown sufficient cell cycle progression. Of CRKs             identified using NCBI conserved domain search facility <br /> with identifiable functions, CRK1 CRK3 appear                     (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) via <br /> required G1/S G2/M phases cell cycle, respectively,          website www.kinase.com. Cyclin kinase domains were <br /> in procyclic bloodstream trypanosomes [23],                  aligned Bootstrap Neighbour Joining trees were <br /> CRK9 shown phosphorylate RNA polymerase II                      generated using ClustalX (1.81) [31]. HyperTree software was <br /> subunit RPB1 required maturation spliced leader            used format output phylogenetic trees [32]. <br /> RNA [24] depletion causes mild defects cell cycle <br /> progression [22]. In addition, CRK2, CRK4 CRK6                     Culturing transfection trypanosomes <br /> been postulated play accessory roles cell cycle progression              T. brucei brucei strain Lister 427 wildtype cell lines (procyclic and <br /> [25]. Functions discerned far cyclins,            bloodstream stages), Lister 427 pHD449 [33] tetracycline induc- <br /> CYC2/CycE1 CYC6/CycB2, gene <span id='am-238' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-239' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-240' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-247' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-249' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-250' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-254' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-259' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-260' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-261' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-266' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-267' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-268' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-270' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-272' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-275' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-277' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-278' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-281' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-286' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-287' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-290' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-292' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-294' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-295' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-296' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-298' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-303' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-306' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-307' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-308' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-309' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-310' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-312' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-314' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-315' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span>knockout</span>                           ible cell lines (procyclic bloodstream stages) RNAi cell <br /> experiments suggest CYC3/CycB1 essential [26], despite              lines 427 pLew13 pLew29 (procyclic form), 427 pLew13 pLew90 <br /> RNAi experiments having yielded detectable phenotype [27].               (bloodstream stage) [34] Lister 427 MITat1.2 clone 221a 2T1 <br /> Depletion CYC2 leads accumulation cells G1/S,            (bloodstream stage) [35], cultured transfected as <br /> in procyclic, bloodstream trypanosomes, accompa-            described previously [29,35,36]. <br /> nied microtubule extension posterior end parasite <br /> [27,28]. Depletion CYC6/CycB2 inhibits mitosis procyclic              Generation CYC9:TAP-expressing procyclic cell lines <br /> and bloodstream T. brucei, fundamental differences            purification CYC9:TAP protein complexes <br /> cell cycle control life cycle stages, downstream effects          To create fusion CYC9 Tandem Affinity Purification <br /> of mitotic inhibition quite different [27,29]. In absence       tag [37] facilitate purification CYC9 protein complexes, <br /> of nuclear division, procyclic trypanosomes continue undergo             39 end CYC9 ORF (Tb11.01.5600) minus stop codon <br /> cytokinesis, bloodstream T. brucei not,           (bp 451&#226;&#8364;&#8220;843) PCR-amplified using oligonucleotides OL1547 <br /> continue replicate DNA organelles [29].                              (incorporating Nco I Xho I restriction sites) OL1548 (with <br />    To date, CRKs demonstrated cyclin-                   Nco I restriction site) (Table S1 oligonucleotides used in <br /> dependent T. brucei. CRK3 shown bind CYC2                 study), sequenced cloned Nco I site pGL900, in <br /> and CYC6 vivo, likely regulates G1/S G2/M            frame downstream TAP sequence. pGL900 derivative <br /> [26,29]. A yeast hybrid study identified interactions           yeast C-terminal TAP tagging vector, pBS1539 (Cellzome), <br /> CRK1 CYC2/CycE1, CYC4/CycE3 CYC5/CycE4,                          cassette consisting BSDR flanked tubulin intergenic <br /> well CRK2 CYC2/CycE1 [30]. However,                    sequences cloned Pst I Apa I sites, replacing <br /> interactions confirmed vivo T. brucei,           URA3 selectable marker. The 39 UTR CYC9 PCR- <br /> previous study indicated that, CYC2 co-immunoprecipitated             amplified oligonucleotides OL1549 OL1550, sequenced <br /> with CRK3, did interact CRK1 CRK2 procyclic               cloned Apa I site pGL900:CYC9:TAP plasmid <br /> T. brucei [26]. Here report identification previously           generating pGL1125. pGL1125 linearised digestion with <br /> uncharacterised CRK:cyclin complex, CRK12:CYC9 T. brucei                 Xho I transfected procyclic form CYC9 single allele <br /> and CRK12 CYC9 essential proteins                 knockout (NEOR) parasites (see below), replace remaining <br /> this important pathogen.                                                    endogenous CYC9 allele CYC9:TAP. The clones obtained <br />                                                                             screened PCR confirm correct integration of <br /> Materials Methods                                                       CYC9:TAP absence wildtype CYC9 alleles. The expression <br />                                                                             CYC9:TAP confirmed Western blotting anti- <br /> Ethics statement                                                            calmodulin binding protein (CBP; Santa Cruz) anti-protein A <br />    Animal work carried study performed            (Sigma) antibodies. <br /> the UK Home Office Licence no. 60/3760 &#226;&#8364;&#732;Biochemistry, genetics                 CYC9:TAP protein complexes purified 8.861010 <br /> and immunology parasitic protozoa&#226;&#8364;&#8482;, approved Animal               cells sequential IgG calmodulin affinity chromatography, <br /> Ethics Committee University Glasgow, licence             according [37], adding 0.5% (rather 0.1%) Nonidet <br /> by Direcc&#194;&#184;a&#203;&#339;o Geral Veterina&#194;&#180;ria (DGV), Portugal, according          P40 (NP40) detergent buffers. The success purification <br /> to national law no. 1005 (<span id='am-2' about='protege:FROM' typeof='owl:Thing'>from</span> 23rd Oct, 1992) University         monitored Western blotting appropriate samples with <br /> Lisbon. All studies carried trained licensed                anti-CBP antibody. Eluates calmodulin column were <br /> personnel strict accordance terms Animal                 analysed nanoflow HPLC electrospray tandem mass spectrom- <br /> (Scientific Procedures) guidelines (1986) recommendations           etry (nLC-ESI-MS/MS). 10 ml eluate mixed 40 ml <br /> in &#226;&#8364;&#732;Responsibility use animals bioscience research:        methanol 50 ml 25 mM ammonium bicarbonate/0.2 mgml21 <br /> Expectations major research council charitable funding           trypsin incubated 37uC overnight. Formic acid was <br /> bodies&#226;&#8364;&#8482; document (UK) national DGV guidelines (Portugal).               added final concentration 1% sample dried via <br /> Mice euthanised parasitaemias reached 109 cells ml21            vacuum centrifugation. Tryptic peptides solubilised 0.5% <br /> by anaesthetising carbon dioxide prior cervical dislocation,        formic acid fractionated nanoflow HPLC system <br /> and efforts minimise suffering.                      (Famos/Switchos/Ultimate, LC Packings) analysed <br />                                                                             electrospray ionisation (ESI) mass spectrometry Q-STARH <br /> Bioinformatic analyses                                                      Pulsar hybrid MS/MS System. Peptide separation was <br />    BLAST searches performed NCBI website (http://              performed Pepmap C18 reversed phase column (LC <br /> blast.ncbi.nlm.nih.gov/Blast.cgi). Pairwise alignments            Packings), using 5 &#226;&#8364;&#8220; 85% acetonitrile gradient (in 0.5% formic <br />  <br />  <br /> PLOS ONE | www.plosone.org                                              2                              June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                         Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br /> acid) run 45 min flow rate 0.2 mlmin21. Mass                    NEOR genes, respectively. The CYC9 knockout plasmids were <br /> spectrometric analysis performed using 3 second survey MS              linearised Xho I prior transfection T. brucei Lister 427 <br /> scan followed MS/MS analyses                       cells. Trypanosomes transfected plasmid individ- <br /> abundant peptides (3 seconds peak) Information Dependent              ually, subjected second transfection the <br /> Acquisition (IDA) mode, choosing 2+ 4+ ions threshold             plasmids, different resistance gene, pairwise <br /> of 30 counts, dynamic exclusion 120 seconds. Data                   combinations performed. <br /> generated analysed using Applied Biosystems Analyst QS <br /> (v1.1) software automated Matrix Science Mascot                      Generation induction RNAi cell lines <br /> Daemon server (v2.1.06) used interrogate T. brucei genome                The RNAit software [41] used identify unique gene <br /> sequences. Protein identifications assigned using Mascot            fragments suitable RNAi studies. For CYC9 RNAi, 408 bp <br /> search engine, gives protein probability based                  fragment CYC9 ORF (bp 335&#226;&#8364;&#8220;742), PCR-amplified <br /> MOWSE score. In cases, variable methionine oxidation                 Lister 427 genomic DNA using oligonucleotides OL2540 <br /> allowed searches carbamidomethylation cysteines                OL2541 (incorporating Hind III Bam HI restriction sites, <br /> selected fixed modification. Mass tolerances 1.2 Da MS           respectively) cloned sites p2T7ti:GFP vector <br /> and 0.4 Da MS/MS analysis used.                                     [42] place GFP coding sequence, generating pGL1759. <br />                                                                              Plasmid pGL1759 linearised digestion Not I, <br /> Generation cell lines expressing tyGFP:CRK12                           transfected 427 pLew13 pLew29 427 pLew13 <br /> ty:CRK12                                                                     pLew90 RNAi cell lines, described independent <br />    To facilitate immunoprecipitation CRK12, tagged              clones cell line selected downstream analyses. <br /> its N-terminus tyGFP follows. The 59 end CRK12                   For RNAi CRK12, 419 bp fragment CRK12 ORF (bp <br /> ORF (Tb11.01.4130) PCR-amplified 427 genomic DNA                    1028&#226;&#8364;&#8220;1446) PCR-amplified TREU 927 genomic DNA <br /> using oligonucleotides PR32 PR33 (introducing Xba I Xho              oligonucleotides OL3387 (incorporating Xma I Xho I <br /> I restriction sites, respectively) 59 end CRK12 ORF           restriction sites) OL3388 (incorporating Bam HI Xba I <br /> was amplified using PR34 PR35 (incorporating Xho I Bam               restriction sites). The product digested Xho I Xba I <br /> HI restriction sites, respectively). Both fragments sequenced           subcloned antisense orientation sites in <br /> and cloned pEnT5-GFP-TY [38] digested Xba I Bam                pRPaiSL (MCS1/2) [35], digested Xma I Bam HI <br /> HI using threeway ligation procedure, generating pHG69,              subcloned sense orientation plasmid, <br /> allows expression tyGFP:CRK12 endogenous locus.                  generating stem-loop construct LACZ stuffer fragment. <br /> pHG69 linearised digestion Xho I prior transfection           The resultant construct (pGL1986) digested Asc I to <br /> into Lister 427 wildtype CYC9:TAP procyclic form cell lines.             release RNAi stem-loop cassette transfected into <br /> Expression tyGFP:CRK12 confirmed Western blotting                  bloodstream 2T1 cells, described above. Hygromycin-resistant <br /> with anti-TY (BB2 antibody; [39]; kind gift Keith                     clones analysed puromycin sensitivity puromy- <br /> Matthews, University Edinburgh) anti-GFP (Santa-Cruz)                 cin-sensitive clones selected downstream analyses. <br /> antibodies.                                                                     The RNAi response induced vitro addition of <br />    Tetracycline inducible cell lines expressing TY-tagged CRK12              1 mgml21 tetracycline culture medium. Knockdown was <br /> (active kinase dead) cell lines generated investigate            confirmed real time PCR, CRK12 RNAi cell lines, also <br /> kinase activity CRK12. The CRK12 ORF amplified                   Western blotting cell lysates specific monoclonal <br /> Lister 427 genomic DNA using PR206 PR207 (incorporating                  antibody. The CRK12 monoclonal antibody generated by <br /> a TY tag Bcl I sites), cloned pSC-B (Stratagene)                immunisation Balb/c mouse purified recombinant <br /> sequenced. To create kinase dead variant CRK12 (K358M),                 6xHis:CRK12 Incomplete Freund&#226;&#8364;&#8482;s Adjuvant (Sigma). Cells <br /> site directed mutagenesis performed cloned CRK12                  spleen removed fused myeloma SP2/0 <br /> sequence oligonucleotides PR208 PR209 using                     AG14 cells cultured DMEM supplemented 5% foetal <br /> QuickChange Site-Directed Mutagenesis kit (Stratagene). The                  bovine serum (Gibco) 37uC, presence 5% CO2, as <br /> CRK12 wildtype kinase dead sequences subcloned                 previously described [43]. Hybridoma supernatants screened <br /> into Bam HI-digested pHD675 [33], generating pHG230                      ELISA Western blot identify anti-CRK12-producing <br /> pHG231, respectively. pHG230 pHG231 linearised                   hybridomas, clone 4D7 selected. The antibody isotype <br /> digestion Not I prior transfecting Lister 427 pHD449            determined IgG using Mouse MonoAB ID (alkaline <br /> [33] cell lines. Inducible expression ty:CRK12 proteins           phosphatase) kit (Zymed), antibody used neat for <br /> confirmed Western blotting anti-TY antibody (as above).              Western blotting. For vivo RNAi CRK12, experimental <br />                                                                              ICR mice injected intraperitoneally 250 ml (56105) <br /> Generation CYC9 knockout cell lines                                       parasites taken donor mouse parasitaemias monitored <br />    Three plasmids (pGL1124, pGL1224 pGL1217)                        daily tail bleed. At 48 hours post-inoculation, when <br /> constructed allow replacement allele CYC9              parasitaemias reached .107 cells ml21, drinking water of <br /> either blasticidin (BSDR), hygromycin (HYGR) neomycin (NEOR)              mice replaced 0.2 mgml21 doxycycline/5% (w/v) <br /> resistance genes, respectively. All plasmids derived               sucrose solution effect induction RNAi response. Mice <br /> pGL802 [40]. The CYC9 open reading frame (ORF) 59 39                     euthanised parasitaemias reached 109 cells ml21. <br /> flanking regions PCR-amplified Lister 427 genomic <br /> DNA using oligonucleotides OL1553 OL1554 (59 flank)                  Real-time PCR analysis <br /> and OL1549 OL1550 (39 flank), cloned Not I/Xba                Total RNA prepared 16108 trypanosome cells using <br /> I Apa I sites pGL802, respectively, using restriction sites       RNeasy Mini kit (Qiagen) treated 2U RNase-free <br /> incorporated oligonucleotide primers, replacing                 DNase I (Ambion) 10 mg RNA 30 minutes 37uC to <br /> flanking regions MCA2 MCA1, generating pGL1124. To                   digest genomic DNA DNase I inactivated with <br /> generate pGL1224 pGL1217, BSDR gene excised                      5 mM EDTA 75uC 10 minutes. 2 mg RNA used in <br /> from pGL1124 digestion Eco RI replaced HYGR                 cDNA synthesis reactions random hexamers (Invitrogen) <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               3                             June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                      Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br /> using Omniscript RT kit (Qiagen), according                    Immunofluorescence analyses <br /> manufacturer&#226;&#8364;&#8482;s protocol. Real time PCR performed                      Cells washed PBS (procyclic form) vPBS (blood- <br /> described previously [44] triplicate (CYC9) quadruplicate           stream form) settled poly-L-lysine coated glass slides <br /> (CRK12). Dissociation curves performed products            (CYC9-TAP) fixed solution (clathrin heavy chain (CLH)). For <br /> check product amplified primer set.             CYC9-TAP immunofluorescence, cells fixed methanol at <br />                                                                           &#226;&#8364;&#8220;20uC 1 hour, transferred PBS bath 5 <br /> Yeast two-hybrid analysis                                                 minutes. Following PBS wash, cells incubated with <br />    To investigate interaction CYC9 CRK12,             1/5000 dilution rabbit anti-protein A antibody 1 hour at <br /> Hybrid Hunter (Invitrogen) used. CYC9 PCR-                 room temperature. To detect CLH, cells fixed 3% PFA for <br /> amplified EATRO 795 genomic DNA oligonucleotides                1 hour 4uC allowed adhere poly-L-lysine <br /> OL1163 OL1164 (introducing Bam HI Hind III sites,                 coated slides 20 minutes. Cells permeabilised PBS/ <br /> respectively), sequenced cloned sites prey       0.1% Triton X-100 neutralised 100 mM glycine, above, <br /> plasmid pYESTrp create pGL932 (expressing B42:CYC9),                   blocked 1 hour PBS/10% foetal calf serum at <br /> while CRK12 amplified OL1600 OL1601 (incorpo-                room temperature incubated 1/500 dilution of <br /> rating Sac I Kpn I sites, respectively), sequenced cloned         rabbit anti-CLH antibody [49] 1 hour room temperature. <br /> into sites bait plasmid pHybLex/Zeo, generating              Following incubation primary antibody, cells washed <br /> pGL1277 (expressing LexA:CRK12). Saccharomyces cerevisiae strain          twice PBS, incubated 1/100 dilution Alexa-Fluor <br /> L40 (Invitrogen) transformed plasmids           594- Alexa-Fluor-488 conjugated anti-rabbit IgG (Invitrogen) <br /> to generate L40 pGL932 pGL1277. As autoactivation controls,           1 hour dark. Cells washed twice 100 mM 4- <br /> empty vector prey bait plasmids transformed L40             (2-hydroxyethyl)piperazine-1-ethanesulphonic acid (HEPES) <br /> together combination pGL932 pGL1277. Positive               pH 7.5, incubated 10 mgml21 DAPI 100 mM HEPES <br /> and negative L40 control strains, expressing LexA:Fos/B42:Jun          pH 7.5 5 minutes, washed twice 100 mM HEPES <br /> LexA:Lamin/B42:Jun, generated using plasmids sup-               pH 7.5 SlowFade Gold antifade reagent (Invitrogen) a <br /> plied Invitrogen. To analyse protein:protein interactions, b-          coverslip added cells observed using DeltaVision <br /> galactosidase histidine prototrophy assays performed             RT epifluorescence imaging (Applied Precision) Soft <br /> according manufacturer&#226;&#8364;&#8482;s instructions previously            WoRx software. <br /> described [45]. <br />                                                                           Uptake assays endocytosis <br /> Immunoprecipitation                                                          Uptake assays performed bloodstream form CRK12 <br />                                            8 <br />    S100 lysates prepared 5610 trypanosome cells              RNAi cell lines using FM4-64FX (N-(3- triethylammonium- <br /> described previously [44]. Soluble cell extracts incubated           propyl) -4-{6-[4-(diethylamino)phenyl]hexatrienyl} pyridinium di- <br /> with anti-glutathione S-transferase (GST, Santa Cruz), anti-TY            bromide) dye (Invitrogen) 4uC 37uC AlexaFluor-594 <br /> (BB2, [39]) anti-rabbit IgG-conjugated Dynabeads (prepared             (AF594)-conjugated human transferrin (Sigma) 37uC essentially <br /> using Immunoprecipitation Kit - DynabeadsH Protein G,                 described [50], cells incubated fluorescent <br /> Invitrogen, according manufacturer&#226;&#8364;&#8482;s instructions) 4uC          cargo 5 minutes. <br /> overnight. Beads washed wash buffer supplied with <br /> the kit supplemented 0.1% Triton X-100 assayed               Transmission Electron Microscopy <br /> kinase activity (below) analysed SDS-PAGE Western                 Specimens prepared viewed described previously <br /> blotting using anti-GFP (Santa Cruz), anti-oligopeptidase B (OPB;         [51]. <br /> [46]) horseradish peroxidise-conjugated anti-PAP (Roche) as <br /> an anti-TAP antibody.                                                     Results <br />                                                                           CYC9 clusters phylogenetically cyclin C <br /> Kinase assays <br />                                                                              CYC9 T. brucei cyclin studied to <br />   Kinase assays performed described previously [47]. <br />                                                                           date. The CYC9 gene comprises 843 bp ORF Rapid <br /> Assay samples electrophoresed SDS-PAGE gels, which <br />                                                                           Amplification cDNA ends (RACE) analysis revealed flanked <br /> were stained Coomassie Blue, dried analysed by <br />                                                                           53 nucleotide 5&#226;&#8364;&#8482; UTR 3&#226;&#8364;&#8482;UTR 230 272 nucleotides <br /> autoradiography. <br />                                                                           depending possible polyadenylation sites used <br />                                                                           (data shown). The CYC9 protein (281 amino acids) contains <br /> ATP assay                                                                 cyclin-like conserved domains (IPRO11028) residues 50- <br />   26107 cells washed Voorheis&#226;&#8364;&#8482; modified phosphate                 144 143-196 transcription regulation cyclin domain <br /> buffered saline (vPBS; [48]), resuspended 300 ml ddH2O             (IPRO15429) residues 36-147 (www.genedb.org). A phyloge- <br /> passed 27G needle times lyse cells. Cellular        netic comparison cyclin domain CYC9 cyclin <br /> debris removed centrifuging 14,000 x g 5 minutes         domains eukaryotic cyclins reveals clusters tightly <br /> 4uC supernatant assayed ATP activity using             CYC9 T. cruzi Leishmania species, clusters more <br /> ATP bioluminescent assay kit (Sigma) EnVision 2102                 closely transcriptional cyclins (human Drosophila cyclins <br /> Multilabel plate reader (Perkin Elmer).                                   C, H, K, L T, fission yeast Srb11, cyclin C <br />                                                                           orthologue) class cyclin (Fig. S1A). <br /> 4,6-Diamidino-2-phenylindole (DAPI) staining flow <br /> cytometry analysis                                                        CYC9 associates CRK12 vivo <br />    The nucleus/kinetoplast configurations DNA content                 To enable functional characterisation CYC9, CYC9 was <br /> cells analyzed DAPI staining conjunction                  tagged C-terminus Tandem Affinity Purification <br /> fluorescence microscopy flow cytometry propidium                (TAP) [37] tag (CYC9:TAP) procyclic T. brucei facilitate the <br /> iodide stained cells, respectively, described previously [29].         identification vivo kinase partner(s) CYC9. A procyclic cell <br />  <br />  <br /> PLOS ONE | www.plosone.org                                            4                             June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                          Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br /> line generated CYC9 allele replaced                   tyGFP:CRK12 CYC9:TAP coprecipitated (Fig. 2C). <br /> CYC9:TAP allele replaced neomycin                     Similarly, anti-rabbit IgG beads immunoprecipitated CYC9:TAP <br /> resistance gene, PCR used confirm correct integration             co-precipitated tyGFP:CRK12 (Fig. 2D), confirming that <br /> (Fig. 1A). Hence, CYC9:TAP expressed copy CYC9               CRK12 CYC9 interact vivo procyclic T. brucei. Tagged <br /> in cell line, data described indicate CYC9         cell lines generated bloodstream form; CYC9:TAP <br /> is essential gene, points CYC9:TAP functional.              interact tyGFP:CRK12 (Fig. S3A) was <br /> Expression CYC9:TAP (51.6 kDa) confirmed Western                   localised nucleus (Fig. S3B) procyclic form. <br /> blotting anti-Calmodulin Binding Protein (CBP) anti-                Bioinformatic searches did reveal presence conven- <br /> protein A antisera (Fig. 1B) immunofluorescence analysis              tional nucleus localisation signal (NLS) CYC9 (data shown), <br /> with anti-protein A antibody, showed CYC9:TAP                does preclude one, NLS consensus <br /> localised nucleus (Fig. 1C). CYC9:TAP expressed                sequences defined T. brucei. <br /> cells cell cycle stages, expected tubulin 39 UTR <br /> sequence downstream tagged gene. CYC9:TAP complexes                   CRK12 autophosphorylates vivo <br /> were purified affinity purification, firstly IgG sepharose.              To determine CRK12 active protein kinase, <br /> Following binding CYC9:TAP complexes beads                 lysates cell lines described (Fig. 2A) incubated <br /> extensive washing, CYC9 complexes released beads               anti-TY beads; beads washed extensively and <br /> by TEV protease cleavage. The resultant CYC9:CBP (35.5 kDa)                  used in vitro kinase assays (Fig. 3). No specific protein kinase <br /> and associated protein(s) bound calmodulin resin,               activity generic substrates (histone H1, myelin basic <br /> washed eluted addition EGTA. The success                protein, alpha beta casein) observed (not shown), a <br /> purification assessed Western blotting anti-CBP (Fig.            protein, consistent size tyGFP:CRK12, present in <br /> 1D). In cell lysate, protein species recognised          assays using cell lysates expressing tyGFP:CRK12 phosphor- <br /> antibody, ,50 kDa, consistent CYC9:TAP,                 ylated (Fig. 3A), indicating tyGFP:CRK12 able to <br /> and smaller ,30 kDa, likely represented                autophosphorylate, protein kinase(s) non-specifically <br /> degradation product CYC9:TAP present             interacting beads was/were able phosphorylate it. <br /> elutions second affinity chromatography step. Following                In order distinguish possibilities, rule <br /> TEV protease treatment, ,35 kDa protein detected,                 observed phosphorylation occurring GFP <br /> likely CYC9:CBP, indicating CYC9:CBP associated                     tag CRK12, new cell lines generated that <br /> protein(s) successfully purified tandem affinity purification.       inducibly expressed ty:CRK12, wildtype (kinase active) or <br /> Mass spectrometry elution 3 identified peptides, KMDAI-               <span id='am-160' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-161' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-165' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-168' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-171' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-176' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-186' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-197' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-200' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-203' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-213' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-223' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-224' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-231' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-234' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span>mutation</span> (K358M) invariant catalytic lysine residue <br /> DEVVRL KKLHEMGIIHRD, corresponded T. brucei                      protein kinase domain predicted result dead kinase. <br /> CRK12 (amino acids 404-414 464-475, respectively), strongly              Both ty:CRK12 ty:CRK12 (K358M) inducibly ex- <br /> suggesting CYC9 binds CRK12 vivo.                                 pressed similar levels following addition tetracycline (Fig. <br />    To confirm interaction CYC9 CRK12,                    3B). Immunoprecipitated wildtype ty:CRK12 phosphorylated <br /> other approaches taken. Firstly, yeast two-hybrid assay           ty:CRK12 (K358M) not, indicating phosphor- <br /> used. The CRK12 CYC9 open reading frames cloned                ylation occurred result autophosphorylation active <br /> the bait (pHybLex/Zeo) prey (pYESTrp) vectors, respectively,             kinase (Fig. 3C). <br /> such CRK12 expressed LexA binding domain fusion <br /> (LexA:CRK12; pGL1277) CYC9 expressed fused                    CYC9 essential procyclic bloodstream stage T. <br /> B42 activating domain (B42:CYC9; pGL932), plasmids                   brucei <br /> were transformed yeast-two hybrid reporter strain L40.                 To investigate function CYC9, attempts to <br /> L40 co-transformed pGL1277 pGL932 plasmids                     knockout CYC9 gene procyclic bloodstream trypano- <br /> exhibited b-galactosidase activity (Fig. S2A), indicating                 somes. First, allele gene replaced a <br /> interaction LexA:CRK12 B42:CYC9,                   blasticidin, neomycin hygromycin resistance marker. Single <br /> LexA:CRK12 B42:CYC9 able induce expression                   allele CYC9 knockout mutants obtained life cycle <br /> of LacZ. Additionally, yeast expressing LexA:CRK12                       stages (Fig. S4) transfected different <br /> B42:CYC9 displayed histidine autotrophy (Fig. S2B), providing                resistance construct try delete second allele. This was <br /> further evidence proteins interact yeast.                      unsuccessful cases; clones obtained the <br />    Secondly, co-immunoprecipitation CRK12 CYC9                   transfection (despite multiple attempts) double drug resistant <br /> T. brucei cell lysates demonstrated (Fig. 2 S3). CRK12           clones subsequently copy CYC9 <br /> tagged N-terminus TY1 [39] GFP epitopes                      present, second drug resistance marker having integrated <br /> (tyGFP:CRK12) facilitate detection, expressed            erroneously genome (Fig. S4). Attempts to <br /> CRK12 endogenous locus wildtype CYC9:TAP                    generate conditional CYC9 null mutant, ectopic copy <br /> background (Fig. 2A). Use tagged CYC9 required                  CYC9 (ha:CYC9) tetracycline-inducible control was <br /> useful anti-CYC9 antibodies generated. Immuno-                  introduced prior knocking second allele, failed. <br /> precipitations performed incubating cell lysates            Overexpression ha:CYC9 stable, expression of <br /> cell lines beads conjugated anti-TY antibody (to precipitate         ha:CYC9 falling undetectable levels days, <br /> tyGFP:CRK12), anti-rabbit IgG (to precipitate CYC9:TAP)                   suggesting overexpression ha:CYC9 toxic. <br /> anti-GST antibody (a specificity control) appropriate samples               An RNAi approach taken investigate CYC9 <br /> analysed Western blotting anti-GFP (to detect                        function. Tetracycline-inducible CYC9 RNAi procyclic and <br /> tyGFP:CRK12), anti-PAP (to detect CYC9:TAP) anti-OPB                     bloodstream cell lines generated, independent <br /> or anti-EF1a (loading control) antibodies (Fig. 2). Anti-GST beads           clones life cycle stage selected downstream <br /> did pull tyGFP:CRK12 CYC9:TAP cell lysates,                 analyses. Induction CYC9 RNAi procyclic T. brucei resulted in <br /> demonstrating proteins bound beads              decreased growth rate growth arrest 120 hours post- <br /> non-specifically (Fig. 2B). Anti-TY beads immunoprecipitated                 induction (Fig. 4A). Real time PCR demonstrated CYC9 <br />  <br />  <br /> PLOS ONE | www.plosone.org                                               5                              June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                                Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 1. Identification CRK12 CYC9 interaction partner using tandem affinity purification. A. Construction procyclic CYC9:TAP <br /> cell line. CYC9 alleles replaced sequentially neomycin resistance (NEO) cassette CYC9:TAP cassette, included blasticidin <br /> resistance marker (BSD) selection, generating cell line expressing CYC9:TAP CYC9 null mutant background. Light grey boxes: CYC9 UTR <br /> sequences; white boxes: tubulin intergenic sequences. PCR (reactions a-e, sizes positions products amplified indicated black bars) used <br /> to verify correct integration cassettes. Reactions (a) (b) (panel (i)), used confirm correct integration NEO cassette single <br /> allele CYC9 knockout line; negative control (&#226;&#8364;&#8220;): procyclic 427 wildtype. Reaction (c) (panel (ii)) used confirm wildtype copy CYC9 no <br /> longer existed CYC9:TAP cell line; positive control (+): procyclic 427 wildtype cell line transfected CYC9:TAP cassette. Reactions (d) (e) <br /> (panel (iii)), used confirm correct integration CYC9:TAP cassette 5&#226;&#8364;&#8482; 3&#226;&#8364;&#8482; ends; positive negative controls (c) (b), <br /> respectively. B. Western blots probed anti-CBP (left), anti-protein A (right, upper blot) EF1a (loading control; right, lower blot) antibodies. <br /> Lane 1: procyclic 427 transfected NEO cassette; lane 2: lane 1 transfected CYC9:TAP construct. Expected size CYC9:TAP is <br /> 51.6 kDa. Asterisk: degradation product; arrowhead: cross-reacting band serves loading control. C. (i) Immunofluorescence analysis of <br /> procyclic CYC9:TAP cell line. Top left: DIC; right: DAPI; left: anti-protein A (CYC9:TAP); right: DAPI/anti-protein A merge. (ii) <br /> Wildtype control. Top: DIC; bottom: DAPI/anti-protein A merge. The configuration nuclei (N) kinetoplasts (K) cell given. Scale bar: 5 mm. <br /> D. Western blot CYC9:TAP purification, probed anti-CBP. In: input IgG column; FT: flow through; W: washes; E: elution fractions. <br /> Expected size CYC9:CBP (after cleavage CYC9:TAP IgG column TEV protease) 35.5 kDa. Asterisk: degradation product. <br /> doi:10.1371/journal.pone.0067327.g001 <br />  <br /> mRNA significantly depleted induced cells 48 hours                   S5A). The proportion 1N1K cells increased slightly, the <br /> post-induction (Fig. 4B). Induction CYC9 RNAi bloodstream                  proportions 1N2K 2N2K cells decreased slightly the <br /> stage T. brucei lead growth arrest, apparent                 induction period, indicating slight accumulation cells (5&#226;&#8364;&#8220;10% <br /> from 12&#226;&#8364;&#8220;18 hours post-induction (Fig. 4C). Real time PCR                         extra 1N1K cells) G1 phase cell cycle. This effect was <br /> indicated CYC9 mRNA reduced 35&#226;&#8364;&#8220;50% 20 hours                       obvious clone 2, CYC9 knocked a <br /> post-induction (Fig. 4D). Thus, CYC9 essential proliferation              greater extent (Fig. 4B). However, depletion CYC9 did not <br /> for procyclic bloodstream stage T. brucei.                              result efficient G1 cell cycle block, abnormal cells <br />                                                                                  including zoids (0N1K), 1N0K 2N1K arose small <br /> CYC9 depletion does result cell cycle block                          numbers following depletion CYC9. Flow cytometry profiles <br /> procyclic T. brucei                                                              (Fig. S5B) consistent DAPI staining; slight increase <br />    To determine growth arrest observed following                     2C peak observed following induction clone 2, a <br /> knockdown CYC9 occurred result cell cycle arrest,                 small ,1C peak appeared later time points, likely <br /> RNAi cells examined DAPI staining determine                       reflecting generation zoids. Thus, CYC9 is <br /> nucleus/kinetoplast (N/K) configurations cells flow                    essential vitro growth T. brucei, does appear play a <br /> cytometry measure DNA content. RNAi CYC9 procyclic                      key role cell cycle progression procyclic trypanosomes. <br /> cells resulted minor changes N/K configurations (Fig. <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                   6                                June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                            Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 2. Co-immunoprecipitation CRK12 CYC9. A. Schematic showing features procyclic cell lines generated. B&#226;&#8364;&#8220;D. <br /> Immunoprecipitation (IP) performed (B) irrelevant antibody (anti-GST), (C) anti-TY antibody (for tyGFP:CRK12) (D) anti-rabbit IgG <br /> (for CYC9:TAP). Samples (In: input; FT: flow through; W1: wash; W4: wash; E: elution) analysed Western blotting anti-GFP to <br /> detect tyGFP:CRK12, anti-PAP detect CYC9:TAP anti-oligopeptidase B (anti-OPB) act loading control input fractions control <br /> for stringency purification. <br /> doi:10.1371/journal.pone.0067327.g002 <br />  <br />  <br />  <br />  <br /> Figure 3. CRK12 active protein kinase. A. Anti-TY immunoprecipitates procyclic cell lysates (1: 427 wildtype; 2: 427 tyGFP:CRK12; 3: <br /> 427 CYC9:TAP; 4: 427 tyGFP:CRK12 CYC9:TAP, Fig. 2A) subjected radiolabelled vitro kinase assay analysed SDS-PAGE and <br /> autoradiography. Lane 5: kinase assay buffer only. Bands likely representing phosphorylated tyGFP:CRK12 (113.5 kDa) indicated. B: Western blot <br /> of 427 cell lysates overexpressing ty:CRK12 (active) kinase dead ty:CRK12 (K358M) response tetracycline (tet) induction. A 427 wildtype cell <br /> lysate included negative control. Western blots probed anti-TY antibody detect ty:CRK12 anti-OPB loading control, as <br /> indicated. C. Immunoprecipitation ty:CRK12 performed using anti-TY beads 427 cell lysates overexpressing ty:CRK12 (active) kinase <br /> dead ty:CRK12 (K358M). 427 wildtype lysates included non-specific binding control. Western blots (left) performed input (In), <br /> flow (FT) elution (E) fractions anti-TY antibody detect ty:CRK12 anti-OPB antibody control non-specific binding to <br /> the beads, indicated. Immunoprecipitates subjected radiolabelled kinase assay (autoradiograph, right). 1: 427 tyGFP:CRK12; 2: 427 <br /> wt; 3: 427 ty:CRK12 (active); 4: 427 ty:CRK12 K358M. Bands likely representing phosphorylation tyGFP:CRK12 (113.5 kDa) ty:CRK12 (86 kDa) are <br /> indicated. <br /> doi:10.1371/journal.pone.0067327.g003 <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                7                               June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                             Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 4. RNAi CYC9 reveals essential viability procyclic bloodstream form trypanosomes. A. Cumulative growth <br /> curves independent procyclic CYC9 RNAi clones (clone 1: C1; clone 2: C2) cultured presence absence tetracycline (tet). B. Real time <br /> PCR analysis CYC9 transcript procyclic CYC9 RNAi clones 1 2 48 hours post-induction. Error bars represent standard deviations three <br /> replicates. The percentage mRNA transcript remaining indicated. C. Cumulative growth curves independent bloodstream CYC9 RNAi <br /> clones (clone 1: C1; clone 2: C2) cultured presence absence tetracycline (tet). D. Real time PCR analysis CYC9 transcript bloodstream <br /> form CYC9 RNAi clones 1 2 20 hours post-induction. Error bars represent standard deviations replicates. <br /> doi:10.1371/journal.pone.0067327.g004 <br />  <br />  <br /> Depletion CYC9 blocks cytokinesis bloodstream                            CRK12 displays similarity PITSLRE protein kinases, but <br /> stage T. brucei                                                                forms separate phylogenetic clade <br />    In contrast depletion CYC9 procyclic trypanosomes,                    CRK12 contains PITSLRE motif PSTAIRE box, <br /> RNAi CYC9 bloodstream parasites resulted aberrant cell                characteristic metazoan CDK11 [52]. BLAST searches were <br /> cycle progression. Since data independent clones              performed CRK12 revealing did display <br /> very similar, data clone presented here. DAPI                  similarity PITSLRE kinases, similar the <br /> staining revealed fold increase 2N2K cells             transcriptional CDKs, CDK9 CDK12 [52] (data shown). <br /> 12 hours induction (Fig. 5A). Examination 2N2K cells                     However, bootstrapped phylogenetic tree of T. brucei <br /> revealed majority cell type                 CRKs, kinetoplastid CRK12 kinases, 21 human CDKs <br /> commenced cytokinesis, time, proportion 2N2K cells                 selected CDKs Drosophila melanogaster Caenorrhabditis <br /> with visible cleavage furrow significantly increased (from 6%&#226;&#8364;&#8220;               elegans revealed kinetoplastid CRK12 proteins formed a <br /> 23% (one way ANOVA; F = 176.58, df = 5, p = 0.00); Fig. 5B).                   separate clade similar T. brucei CRK8 and <br /> Taken together, data suggest depletion CYC9 inhibits             CRK11 PITSLRE clade (Fig. S1B). Thus CRK12 <br /> cytokinesis. At 18 hours post-induction, population cells            novel functions T. brucei. <br /> abnormal N/K configurations (many contained multiple <br /> nuclei kinetoplasts) increased ploidy detected                  CRK12 essential protein bloodstream stage T. <br /> DAPI staining (&#226;&#8364;&#732;others&#226;&#8364;&#8482; Fig. 5A) flow cytometry (Fig. 5C; 8C            brucei <br /> peak), respectively. While multi-nucleate cells did                 To investigate function CRK12, RNAi used to <br /> not appear commenced cytokinesis (Fig. 5Di iii),                   deplete CRK12 T. brucei. Previously, downregulation of <br /> others observed invagination anterior end             CRK12 procyclic T. brucei did lead discernible <br /> (Fig. 5Dii iv), suggesting attempted begin furrow              phenotype [22], work focussed bloodstream <br /> ingression, observed attempting undergo                 stage. Tetracycline-induction independent CRK12 blood- <br /> abscission, cells observed                    stream stage RNAi cell lines arrested growth 18 hours, and <br /> multiple cell bodies attached posterior ends (Fig. 5Dv),        cells died following longer exposure tetracycline (Fig. 6A). <br /> it likely completion cytokinesis inhibited (Fig. 5D).           CRK12 mRNA depleted 30% uninduced levels at <br />                                                                                18 hours post-induction (Fig. 6B) Western blotting an <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                 8                               June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                             Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 5. Depletion CYC9 bloodstream form inhibits cytokinesis. A. DAPI staining nuclei (N) kinetoplasts (K) time <br /> points indicated (post-induction). .200 cells time point classified according N/K configuration. B. Cytokinesis stage analysis 2N2K <br /> cells. 2N2K cells (n . 200/timepoint) scored differential interference contrast (DIC) microscopy visible cleavage <br /> furrow (furrow ingression) undergoing abscission. Error bars represent standard deviations replicate experiments. C. Flow <br /> cytometry analysis propidium iodide stained cells time points indicated (in hours). The ploidies peaks indicated. D. Example <br /> images multinucleate/kinetoplast cells. Left panels: DIC image; right panels: DAPI staining. The N/K configuration cell indicated. Scale <br /> bars: 5 mm. Arrows indicate partially ingressed cleavage furrows. <br /> doi:10.1371/journal.pone.0067327.g005 <br />  <br /> anti-CRK12 monoclonal antibody demonstrated CRK12                         kinetoplast positioning 1N2K 2N2K cells 12 and <br /> protein substantially depleted 12 hours RNAi                 18 hours post-induction (Fig. 7A,B), observed in <br /> induction (Fig. 6C). Western blotting cell extracts procyclic             uninduced cells. Instead kinetoplasts arranged <br /> and bloodstream cell lines overexpressing ty:CRK12 confirmed                   longitudinally cell axis, 1N2K 2N2K cells with <br /> the specificity antibody. However, attempts detect               kinetoplasts positioned laterally cell accumu- <br /> CRK12 immunofluorescence unsuccessful date.                    lated (Fig. 7A&#226;&#8364;&#8220;C). Many cells enlarged flagellar <br /> The importance CRK12 proliferation bloodstream T.                    pockets (Fig. 7C&#226;&#8364;&#8220;F), visualised DIC microscopy <br /> brucei mouse model investigated. Mice                       (Fig. 7C,D) TEM (Fig. 7E), caused the <br /> inoculated CRK12 RNAi trypanosomes RNAi                           distortion kinetoplast position. 1N1K cells enlarged <br /> response induced doxycycline added drinking water.                flagellar pocket observed occasionally (Fig. 7C), the <br /> Non-doxycycline treated mice culled 72 hours post-                flagellar pocket enlargement substantial 1N2K and <br /> infection high parasitaemias, doxycycline-                  2N2K cells, suggesting flagellar pocket enlargement increased <br /> treated mice detectable parasitaemia 72 96 hours                  cell progressed cell cycle. The majority 2N2K <br /> post-infection (Fig. 6D), indicating CRK12 essential               cells able undergo cytokinesis regardless they <br /> survival T. brucei mice.                                                 possessed enlarged flagellar pockets, defects cytokinesis <br />                                                                                observed cells (Fig. 7D). <br /> Depletion CRK12 results enlargement                                  An enlarged flagellar pocket previously linked to <br /> flagellar pocket defects endocytosis                                    defects endocytosis [53]. To determine CRK12- <br />   Cell cycle progression examined CRK12 RNAi cell lines                 depleted cells enlarged flagellar pockets defects in <br /> cultured vitro. DAPI staining (Fig. 6E) flow cytometry (data            endocytosis, uptake fluorescent lipophilic dye, FM4-64, was <br /> not shown) did reveal major defects cell cycle                      analysed. While FM4-64 efficiently taken internalised <br /> progression. However, closer examination revealed defects                   uninduced cells 4uC 37uC (Fig. 8A, left panels), as <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                 9                               June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                             Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 6. CRK12 essential viability bloodstream form. A. Cumulative growth curves CRK12 RNAi clones (C1 C2) <br /> cultured presence absence tetracycline (tet). B. Real time PCR analysis CRK12 transcript 18 hours post-induction (% mRNA transcript <br /> remaining indicated). Error bars: standard deviations replicates. C. Western blot analysis CRK12 protein depletion following RNAi <br /> induction. Cell lysates (106 cell equivalents/lane) CRK12 RNAi clone 1 0, 12 24 hours post-induction analysed Western blotting with <br /> anti-CRK12 antibody (upper blot). CRK12/ty:CRK12 (85/86 kDa) indicated. To demonstrate anti-CRK12 monoclonal antibody specificity, procyclic <br /> (PCF) bloodstream form (BSF) cell lysates 427 wildtype (WT) 427 pHD449 pHG230 (ty:CRK12 inducible overexpression cell line, OE, induced <br /> (+) (&#226;&#8364;&#8220;) tetracycline 24 (bloodstream form) 48 (procyclic form) hours) blotted. As loading control, blots probed with <br /> anti-EF1a antibody (lower blot). D. Growth curves CRK12 RNAi cell lines mouse model. Mice inoculated intraperitoneally 56105 <br /> parasites day 0; mice 3 4 provided doxycycline drinking water day 2 (indicated arrow) induce RNAi. Mice 1 and <br /> 2 euthanised day 3 high parasitaemias. E. DAPI staining nuclei (N) kinetoplasts (K) time points indicated CRK12 <br /> RNAi clones 1 2 induced tetracycline (tet). .200 cells time point classified according N/K configuration. <br /> doi:10.1371/journal.pone.0067327.g006 <br />  <br /> by induced CRK12 RNAi cells obvious enlargement                     inhibited induced CRK12 RNAi cells enlarged flagellar <br /> their flagellar pocket (Fig. 8A, middle panels), induced cells            pockets. Uptake AF594-transferrin 37uC examined <br /> enlarged flagellar pockets showed FM4-64 signal                       CRK12 RNAi cells. In contrast FM4-64, AF 594-transferrin, <br /> identical conditions (Fig. 8A, right panels). We                     taken receptor-linked endocytosis [54], not <br /> hypothesised cells significant flagellar pocket defects              internalised induced CRK12 RNAi cells remained the <br /> were unable internalise dye blocked endocytosis,             flagellar pocket, regardless pocket size (Fig. 8C). Thus appears <br /> that dye diffused flagellar pocket cells              depletion CRK12 blocks receptor-linked endocytosis <br /> were washed prior imaging. The trypanosome clathrin heavy                   (AF594-transferrin), blocks endocytosis FM4-64 in <br /> chain (CLH) required endocytosis flagellar pocket,           cells. Since endocytosis BSF parasites energetically <br /> localises numerous tubule-vesicular structures cytoplasm             expensive, ATP levels assayed determine CRK12 <br /> [49]. Immunofluorescence anti-CLH antibody revealed                  depletion resulted reduction intracellular ATP concentra- <br /> normal distribution CLH uninduced induced CRK12                      tion account observed defects endocytosis. <br /> RNAi cells enlarged flagellar pockets, CRK12 RNAi               However, ATP levels induced CRK12 RNAi cells to <br /> cells enlarged flagellar pockets, clathrin internalised           equivalent uninduced wildtype 427 cells (Fig. <br /> and instead restricted periphery flagellar pocket            8D). <br /> (Fig. 8B), corroborating FM4-64 data endocytosis is <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                10                               June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                              Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 7. Depletion CRK12 bloodstream form T. brucei results defect endocytosis. A B. Quantification 1N2K 2N2K <br /> cells, respectively, normal abnormal kinetoplast positioning 12 18 hours post-induction tetracycline (tet). No cells observed <br /> to abnormal kinetoplast positioning 0 hours. n .200 cells/time point. C. Visualising enlarged flagellar pockets mispositioned <br /> kinetoplasts. Uninduced cells shown comparison. Example images induced cells abnormally enlarged flagellar pocket <br /> regions (one example indicated arrow) shown below. From left right: DIC image, DAPI image, DIC/DAPI merge. The N/K configuration of <br /> each cell indicated. Note lateral positioning 2 kinetoplasts induced cells (indicated asterisks) compared longitudinal <br /> positioning uninduced cells. Scale bar: 10 mm. D. Example images cells abscission enlarged flagellar pocket regions. From left right: <br /> DIC image, DAPI image, DIC/DAPI merge. Scale bar: 10 mm. E. Transmission electron microscopy (TEM) images flagellar pockets CRK12 RNAi cells <br /> induced (+) (&#226;&#8364;&#8220;) tetracycline (tet) (t = 18 hrs). A: axoneme; BB: basal body; FP: flagellar pocket; K: kinetoplast. Scale bars: 500 nm. F. <br /> Quantification 1N2K (top) 2N2K (bottom) cells normal enlarged flagellar pockets (FP) 12 18 hours post-induction with <br /> tetracycline (tet). No cells observed enlarged flagellar pockets 0 hours. n .200 cells/time point. <br /> doi:10.1371/journal.pone.0067327.g007 <br />  <br />  <br /> Discussion                                                                      study published recently, identified CRK12 as <br />                                                                                 essential protein kinase bloodstream form T. brucei [55]. In <br />    We report identification characterisation               contrast, CRK12 required proliferation of <br /> CRK:cyclin complex vivo T. brucei. CRK12:CYC9 interact                 procyclic T. brucei [22], given apparent role CRK12 <br /> a yeast two-hybrid assay form active protein kinase                      endocytosis (see below), reflect downregulation of <br /> complex procyclic bloodstream form T. brucei. Intriguingly,              endocytosis life cycle stage [56], hypothesised to <br /> although CRK12 able autophosphorylate, unable                  account stage-specific differences sensitivity depletion of <br /> phosphorylate common generic CDK substrates, suggest-                   late endosomal protein, RAB7 [57]. Our data provide genetic <br /> ing narrow substrate specificity. Given              validation CRK12:CYC9 potential novel drug target for <br /> this CDK linked role endocytosis (see                African trypanosomiasis future work focus on <br /> below), perform function phosphorylating                       identifying substrates allow development vitro assay <br /> trypanosome-specific substrate.                                                 kinase complex facilitate high throughput <br />    RNAi depletion experiments indicate partner proteins               screening small molecule inhibitors. <br /> are essential; CYC9 essential proliferation culture                  This study began functional characterisation of <br /> both procyclic bloodstream trypanosomes, CRK12                    CRK12:CYC9. CYC9 closely clusters phylogenetically with <br /> found essential proliferation bloodstream trypano-                 transcriptional cyclins. CRK12 &#226;&#8364;&#732;PITSLRE&#226;&#8364;&#8482; motif its <br /> somes vitro vivo mice. Our CRK12 data agreement              protein kinase domain located C-terminus the <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                 11                               June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                              Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br />  <br /> Figure 8. CRK12 depleted bloodstream form T. brucei exhibit defective FM4-64 uptake receptor-linked endocytosis. A. FM4-64 <br /> uptake assay 4uC 37uC CKR12 RNAi cells (clone 1) induced tetracycline (tet) 18 hours. For pair images: left: DIC <br /> images; right: DAPI (white)/FM4-64 (red) merge. Two sets + tet images shown: enlarged flagellar pockets (centre panels) and <br /> those enlarged flagellar pockets (right panels, indicated arrows). B. Clathrin heavy chain (CHC) immunofluorescence analysis CRK12 RNAi <br /> cells (clone 1) induced tetracycline (tet) 12 hours. Left: DIC images; right: DAPI (white)/CHC (green). Induced cells exhibiting normal <br /> (upper panels) enlarged (lower panels, indicated arrow) flagellar pockets shown. C. AF594-transferrin uptake assay 37uC CKR12 <br /> RNAi cells (clone 1) induced tetracycline (tet) 18 hours. Left: DIC images; right: DAPI (white)/AF594-transferrin (red) merge. Scale bars: <br /> 10 mm. D. Bioluminescent intracellular ATP assay 427 wildtype CRK12 RNAi cells (induced tetracycline (tet)). Assays were <br /> performed quadruplicate luminescence obtained averaged normalised wildtype control. Error bars standard <br /> deviations. <br /> doi:10.1371/journal.pone.0067327.g008 <br />  <br /> protein [20] resembles PITSLRE kinases including                       PITSLRE transcriptional CDK clades, may <br /> metazoan CDK11 [58]. There isoforms CDK11                           evolved novel functions. Indeed, depletion of <br /> [59,60], regulate splicing transcription [58,61&#226;&#8364;&#8220;              CRK12 bloodstream stage T. brucei resulted flagellar <br /> 63] required centrosome maturation, mitotic                pocket enlargement, suggestive defect endocytosis [53]. Our <br /> spindle formation sister chromatid cohesion [64,65],                 data showing lack AF594-transferrin internalisation, reduction <br /> involved cytokinesis [66&#226;&#8364;&#8220;69]. BLAST analyses revealed                   FM4-64 uptake mislocalisation clathrin heavy chain <br /> similarity CRK12 transcriptional kinases CDK9                   following CRK12 depletion supports CRK12 playing critical <br /> and CDK12. However, phylogenetic analysis shows                        role endocytosis, function knowledge, not <br /> trypanosomatid CRK12 proteins form clade separate                     described CDK previously. CRK12 directly <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                 12                               June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                          Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br /> regulate endocytosis, phosphorylating component                  font, CRK12 kinetoplastid cluster shaded red the <br /> endocytic machinery, indirectly phosphorylating            PITSLRE kinases clade shaded blue. <br /> a nuclear factor regulates expression genes involved          (PDF) <br /> endocytosis. Future work focus determining                     Figure S2 CRK12 CYC9 interact yeast two <br /> localisation CRK12 help shed light function.            hybrid assay. A: b-galactosidase assay transcription LacZ <br /> We not, however, detect role CRK12 regulating             reporter gene. (a): L40 pHybLex/Zeo pYESTrp; (b): L40 <br /> T. brucei cell cycle.                                                        pGL1277 (LexA:CRK12) pYESTrp; (c): L40 pHybLex/Zeo <br />     Depletion CYC9 gave rise different phenotypes                   pGL932 (B42:CYC9); (d): L40 pGL1277 pGL932. B. Histidine <br /> bloodstream procyclic life cycle stages,              prototrophy assay. Colonies yeast strain L40 expressing <br /> to CYC9 interacting additional different CRKs                    LexA:Fos/B42:Jun (positive control), LexA:Lamin/B42:Jun (neg- <br /> different life cycle stages, CRK12:CYC9 phosphory-                ative control) LexA:CRK12/B42:CYC9 (two independent <br /> lates different substrates according life cycle stage. In             transformants) suspended PBS, diluted indicated and <br /> bloodstream stage T. brucei, depletion CYC9 rapidly led          spotted minimal medium plates containing (+) lacking (-) <br /> fold increase 2N2K cells increased proportion                     histidine (His). <br /> undergoing furrow ingression, later, cells continued            (PDF) <br /> re-replicate organelles despite having completed division, <br />                                                                              Figure S3 CYC9:TAP interacts ty:CRK12 blood- <br /> and attempted divide again, resulting cells multiple <br /> cell bodies. Given nuclear localisation, similarity           stream form T. brucei. A. Immunoprecipitation (IP) of <br />                                                                              ty:CRK12. Cell lysates co-expressing CYC9:TAP (from the <br /> transcriptional cyclins, unlikely CYC9 directly effects <br />                                                                              endogenous locus) ty:CRK12 (under tetracycline inducible <br /> cytokinesis, regulate gene expression cytokinesis <br />                                                                              control) incubated anti-TY (left panel) anti- <br /> effectors expressed constitutively cell <br />                                                                              rabbit IgG beads (right panel) beads washed and <br /> cycle, Polo-like kinase [70,71]. In comparison the <br />                                                                              proteins remaining eluted beads. Samples input <br /> bloodstream form, alterations cell cycle progression were <br />                                                                              (In), flow (FT), washes 1 3 (W1 W3) the <br /> detected following CYC9 depletion procyclic T. brucei, thus, <br />                                                                              elution (E) analysed Western blotting anti-PAP, anti- <br /> if CYC9 does regulate gene expression, regulate expression <br />                                                                              TY anti-EF1-a (specificity control) indicated. D: Immuno- <br /> of different genes life cycle stage.                                 fluorescence analysis bloodstream cell line expressing CY- <br />     Different phenotypes observed following CYC9                    C9:TAP. Top right: DIC; left: DAPI stain DNA; bottom <br /> CRK12 depletion bloodstream stage T. brucei,                    left: anti-protein A (to detect CYC9:TAP); right: DAPI/ <br /> intriguing given form complex. This indicate            anti-protein A merge. Scale bar: 5 mm. <br /> CYC9 and/or CRK12 interact additional partners                       (PDF) <br /> perform distinct functions, differentially affected <br /> by individual RNAi knockdowns. Alternatively, possible             Figure S4 PCR analysis putative CYC9 knockout cell <br /> that CYC9 and/or CRK12 play roles                          lines. Five putative double knockout clonal procyclic cell lines (A) <br /> cytokinesis endocytosis, functional redundancy                putative double knockout clonal bloodstream cell line (B) <br /> these pathways mean potential endocytosis function            (each resistant different selective drugs) analysed by <br /> CYC9 potential cytokinesis function CRK12 provided               PCR alongside appropriate control cells lines (see keys part <br /> by cyclin CDK, respectively, absence.                    figure). PCR primers designed test correct integration of <br /> Additionally, threshold level CYC9 CRK12 required                  59 39 flanks drug resistance markers used as <br /> for functions different, depletion           presence drug resistance marker ORF, presence <br /> CYC9 CRK12 sufficient disrupt cytokinesis                    intact copy CYC9 gene. The expected size each <br /> endocytosis, both.                                                   fragment indicated. L: 1 kb DNA ladder (see key for <br />                                                                              fragment sizes); KO: knockout; HYG, NEO, BSD: resistance genes <br />     Our functional characterisation CYC9 provides additional <br />                                                                              hygromycin, neomycin blasticidin, respectively. <br /> evidence cell cycle regulation varies considerably the <br />                                                                              (PDF) <br /> life cycle T. brucei, analysis CRK12 demonstrates <br /> for time trypanosomatid CRK functions                 Figure S5 Depletion CYC9 procyclic T. brucei does <br /> limited cell cycle regulation. Additionally, work genetically         result significant cell cycle defect. A: DAPI <br /> validates novel CRK:cyclin complex potential drug target           staining procyclic form CYC9 RNAi cell lines. Cells stained <br /> this devastating human animal pathogen.                                  DAPI number nuclei (N) kinetoplasts (K) per <br />                                                                              cell quantified time points indicated hours (n .300 cells <br /> Supporting Information                                                       time point). B: Flow cytometry analysis procyclic form CYC9 <br />                                                                              RNAi. Cells stained propidium iodide analysed by <br /> Figure S1 Phylogenetic analysis CYC9 CRK12. A:                        flow cytometry time points indicated following induction <br /> Phylogenetic analysis CYC9. The cyclin domains CYC9                tetracycline (tet). The ploidies peaks indicated. <br /> other selected kinetoplastid, human (H. sapiens), Drosophila (D.             (PDF) <br /> melanogaster) yeast (S. pombe) cyclins aligned and <br />                                                                              Table S1 Oligonucleotides used study. <br /> bootstrapped described Materials Methods. T. brucei <br />                                                                              (DOCX) <br /> cyclins highlighted bold font, transcriptional cyclins in <br /> red font, mitotic cyclins blue font stress response cyclins in <br /> green font. The CYC9 kinetoplastid cluster shaded red. B:              Acknowledgments <br /> Phylogenetic analysis CRK12. The kinase domains CRK12                  We thank Christina Naula constructing pGL900, Jim Scott for <br /> and selected kinetoplastid, human, Drosophila worm (C.             constructing pHG69 performing anti-protein A Western blot in <br /> elegans) CDKs aligned bootstrapped described              Fig. 1A, Keith Matthews kind gift BB2 antibody, Margaret <br /> Materials Methods. T. brucei CRKs highlighted bold                Mullin preparation electron microscopy specimens Mark Field <br />                                                                              helpful discussions providing CLH antibody. <br />  <br />  <br /> PLOS ONE | www.plosone.org                                              13                              June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                                                     Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br />  <br /> Author Contributions                                                                              TCH. Analyzed data: SM CIAC AF CB RB JCM TCH. Contributed <br />                                                                                                   reagents/materials/analysis tools: CN. Wrote paper: TCH. Com- <br /> Conceived designed experiments: SM CIAC AF CB LT RB CN                                    mented draft manuscript: SM CIAC CB RB CN JCM. <br /> JCM TCH. Performed experiments: SM CIAC AF CB AH LT RB <br />  <br /> References <br />  1. Satyanarayana A, Kaldis P (2009) Mammalian cell-cycle regulation:                     27. Li Z, Wang CC (2003) A PHO80-like cyclin B-type cyclin control cell <br />     Cdks, numerous cyclins diverse compensatory mechanisms. Oncogene 28:                          cycle procyclic form Trypanosoma brucei. J Biol Chem 278: 20652&#226;&#8364;&#8220;20658. <br />     2925&#226;&#8364;&#8220;2939. onc2009170 [pii];10.1038/onc.2009.170 [doi].                                       28. Hammarton TC, Engstler M, Mottram JC (2004) The Trypanosoma brucei cyclin, <br />  2. Enserink JM, Kolodner RD (2010) An overview Cdk1-controlled targets                        CYC2, required cell cycle progression G1 phase maintenance <br />     processes. Cell Div 5: 11. 1747-1028-5-11 [pii];10.1186/1747-1028-5-11 [doi].                     procyclic form cell morphology. J Biol Chem 279: 24757&#226;&#8364;&#8220;24764. <br />  3. Nigg EA (1995) Cyclin-dependent protein kinases: Key regulators                        29. Hammarton TC, Clark J, Douglas F, Boshart M, Mottram JC (2003) Stage- <br />     eukaryotic cell cycle. Bioessays 17: 471&#226;&#8364;&#8220;480.                                                     specific differences cell cycle control Trypanosoma brucei revealed RNA <br />  4. Shiekhattar R, Mermelstein F, Fisher RP, Drapkin R, Dynlacht B, et al. (1995)                     interference mitotic cyclin. J Biol Chem 278: 22877&#226;&#8364;&#8220;22886. <br />     Cdk-activating kinase complex component human transcription factor                    30. Gourguechon S, Savich JM, Wang CC (2007) The multiple roles cyclin E1 in <br />     TFIIH. Nature 374: 283&#226;&#8364;&#8220;287.                                                                       controlling cell cycle progression cellular morphology Trypanosoma brucei. J <br />  5. Glover-Cutter K, Larochelle S, Erickson B, Zhang C, Shokat K, et al. (2009)                       Mol Biol 368: 939&#226;&#8364;&#8220;950. S0022-2836(07)00231-8 [pii];10.1016/ <br />     TFIIH-associated Cdk7 kinase functions phosphorylation C-terminal                           j.jmb.2007.02.050 [doi]. <br />     domain Ser7 residues, promoter-proximal pausing, termination RNA                       31. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The <br />     polymerase II. Mol Cell Biol 29: 5455-5464. MCB.00637-09 [pii];10.1128/                           CLUSTAL_X windows interface: flexible strategies multiple sequence <br />     MCB.00637-09 [doi].                                                                               alignment aided quality analysis tools. Nucleic Acids Res 25: 4876&#226;&#8364;&#8220;4882. <br />  6. Choo S, Schroeder S, Ott M (2010) CYCLINg transcription:                                  gka797 [pii]. <br />     posttranslational modifications P-TEFb regulate transcription elongation.                  32. Bingham J, Sudarsanam S (2000) Visualizing large hierarchical clusters in <br />     Cell Cycle 9: 1697&#226;&#8364;&#8220;1705. 11346 [pii].                                                             hyperbolic space. Bioinformatics 16: 660&#226;&#8364;&#8220;661. <br />  7. Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ (2009) The human CDK8                            33. Biebinger S, Wirtz E, Lorenz P, Clayton CE (1997) Vectors inducible <br />     subcomplex molecular switch controls Mediator coactivator function.                     expression toxic gene products bloodstream procyclic Trypanosoma <br />     Genes Dev 23: 439&#226;&#8364;&#8220;451. 23/4/439 [pii];10.1101/gad.1767009 [doi].                                  brucei. Mol Biochem Parasitol 85: 99&#226;&#8364;&#8220;112. <br />  8. Yang Z, Geng J, Yen WL, Wang K, Klionsky DJ (2010) Positive negative                       34. Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible <br />     roles different cyclin-dependent kinase Pho85-cyclin complexes orchestrate                     expression conditional gene knock-outs dominant-negative <br />     induction autophagy Saccharomyces cerevisiae. Mol Cell 38: 250&#226;&#8364;&#8220;264. S1097-                  genetics Trypanosoma brucei. Mol Biochem Parasitol 99: 89&#226;&#8364;&#8220;101. <br />     2765(10)00250-9 [pii];10.1016/j.molcel.2010.02.033 [doi].                                     35. Alsford S, Horn D (2008) Single-locus targeting constructs reliable regulated <br />  9. Hisanaga SI, Endo R (2010) Regulation role cyclin-dependent kinase                         RNAi transgene expression Trypanosoma brucei. Mol Biochem Parasitol <br />     activity neuronal survival death. J Neurochem 115: 1309-1321. 10.1111/                     161: 76-79. S0166-6851(08)00136-9 [pii];10.1016/j.molbiopara.2008.05.006 <br />     j.1471-4159.2010.07050.x [doi].                                                                   [doi]. <br /> 10. Lenburg ME, Oshea EK (1996) Signaling phosphate starvation. Trends                         36. Burkard G, Fragoso CM, Roditi I (2007) Highly efficient stable transformation <br />     Biochemical Sciences 21: 383&#226;&#8364;&#8220;387.                                                                 bloodstream forms Trypanosoma brucei. Mol Biochem Parasitol 153: 220&#226;&#8364;&#8220;223. <br /> 11. Nishizawa M, Tanigawa M, Hayashi M, Maeda T, Yazaki Y, et al. (2010) Pho85                    37. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, et al. (1999) A generic <br />     kinase, cyclin-dependent kinase, regulates nuclear accumulation Rim101                   protein purification method protein complex characterization proteome <br />     transcription factor stress response Saccharomyces cerevisiae. Eukaryot Cell            exploration. Nat Biotechnol 17: 1030&#226;&#8364;&#8220;1032. <br />     9: 943&#226;&#8364;&#8220;951. EC.00247-09 [pii];10.1128/EC.00247-09 [doi].                                      38. Kelly S, Reed J, Kramer S, Ellis S, Webb H, et al. (2007) Functional genomics in <br /> 12. Morgan DO (1995) Principles CDK regulation. Nature 374: 131&#226;&#8364;&#8220;134.                               Trypanosoma brucei: collection vectors expression tagged proteins <br /> 13. Bloom J, Cross FR (2007) Multiple levels cyclin specificity cell-cycle control.             endogenous ectopic gene loci. Mol Biochem Parasitol 154: 103&#226;&#8364;&#8220;109. <br />     Nat Rev Mol Cell Biol 8: 149&#226;&#8364;&#8220;160. nrm2105 [pii];10.1038/nrm2105 [doi].                        39. Bastin P, Bagherzadeh A, Matthews KR, Gull K (1996) A novel epitope tag <br /> 14. Barette C, Jariel-Encontre I, Piechaczyk M, Piette J (2001) Human cyclin C                        study protein targeting organelle biogenesis Trypanosoma brucei. <br />     protein stabilized associated kinase cdk8, independently catalytic               Mol Biochem Parasitol 77: 235&#226;&#8364;&#8220;239. <br />     activity. Oncogene 20: 551&#226;&#8364;&#8220;562.                                                               40. Helms MJ, Ambit A, Appleton P, Tetley L, Coombs GH, et al. (2006) <br /> 15. Kiernan RE, Emiliani S, Nakayama K, Castro A, Labbe JC, et al. (2001)                             Bloodstream form Trypanosoma brucei depend multiple metacaspases <br />     Interaction cyclin T1 SCF(SKP2) targets CDK9 ubiquitination                       associated RAB11-positive endosomes. J Cell Sci 119: 1105&#226;&#8364;&#8220;1117. <br />     degradation proteasome. Mol Cell Biol 21: 7956&#226;&#8364;&#8220;7970. 10.1128/ <br />                                                                                                   41. Redmond S, Vadivelu J, Field MC (2003) RNAit: automated web-based tool <br />     MCB.21.23.7956-7970.2001 [doi]. <br />                                                                                                       selection RNAi targets Trypanosoma brucei. Mol Biochem Parasitol <br /> 16. Tassan J-P, Schultz SJ, Bartek J, Nigg EA (1994) Cell cycle analysis the <br />                                                                                                       128: 115&#226;&#8364;&#8220;118. <br />     activity, subcellular localization, subunit composition human CAK <br />                                                                                                   42. LaCount DJ, Bruse S, Hill KL, Donelson JE (2000) Double-stranded RNA <br />     (CDK-activating kinase). J Cell Biol 127: 467&#226;&#8364;&#8220;478. <br />                                                                                                       interference Trypanosoma brucei using head-to-head promoters. Mol Biochem <br /> 17. Tsai L-H, Delalle I, Caviness VS, Jr., Chae T, Harlow E (1994) p35 neural- <br />                                                                                                       Parasitol 111: 67&#226;&#8364;&#8220;76. <br />     specific regulatory subunit cyclin-dependent kinase 5. Nature 371: 419&#226;&#8364;&#8220;423. <br />                                                                                                   43. Kohler G, Milstein C (1975) Continuous cultures fused cells secreting <br /> 18. Tang DM, Yeung J, Lee KY, Matsushita M, Matsui H, et al. (1995) An isoform <br />                                                                                                       antibody predefined specificity. Nature 256: 495&#226;&#8364;&#8220;497. <br />     neuronal cyclin-dependent kinase 5 (Cdk5) activator. J Biol Chem 270: <br />                                                                                                   44. Ma JT, Benz C, Grimaldi R, Stockdale C, Wyatt P, et al. (2010) Nuclear DBF-2- <br />     26897&#226;&#8364;&#8220;26903. <br />                                                                                                       related Kinases essential regulators cytokinesis bloodstream stage <br /> 19. Tang DM, Chun ACS, Zhang MJ, Wang JH (1997) Cyclin-dependent kinase 5 <br />                                                                                                       Trypanosoma brucei. J Biol Chem 285: 15356&#226;&#8364;&#8220;15368. <br />     (CdkB) activation domain neuronal Cdk5 activator - Evidence existence <br />     cyclin fold neuronal Cdk5a activator. J Biol Chem 272: 12318&#226;&#8364;&#8220;12327.                     45. Hammarton TC, Ford JR, Mottram JC (2000) Trypanosoma brucei CYC1 does not <br />                                                                                                       characteristics mitotic cyclin. Mol Biochem Parasitol 111: 229&#226;&#8364;&#8220;233. <br /> 20. Hammarton TC (2007) Cell cycle regulation Trypanosoma brucei. Mol Biochem <br />     Parasitol 153: 1&#226;&#8364;&#8220;8.                                                                           46. Munday JC, McLuskey K, Brown E, Coombs GH, Mottram JC (2010) <br /> 21. Naula C, Parsons M, Mottram JC (2005) Protein kinases drug targets                          Oligopeptidase B deficient mutants Leishmania major. Mol Biochem Parasitol. <br />     trypanosomes Leishmania. Biochimica et Biophysica Acta-Proteins                           S0166-6851(10)00234-3 [pii];10.1016/j.molbiopara.2010.09.003 [doi]. <br />     Proteomics 1754: 151&#226;&#8364;&#8220;159.                                                                     47. Mottram JC, Grant KM (1996) Leishmania mexicana p12cks1, functional <br /> 22. Gourguechon S, Wang CC (2009) CRK9 contributes regulation mitosis                           homologue fission yeast p13suc1, associates stage-regulated histone <br />     cytokinesis procyclic form Trypanosoma brucei. BMC Cell Biol 10: 68.                H1 kinase. Biochem J 316: 833&#226;&#8364;&#8220;839. <br />     1471-2121-10-68 [pii];10.1186/1471-2121-10-68 [doi].                                          48. Nolan DP, Jackson DG, Biggs MJ, Brabazon ED, Pays A, et al. (2000) <br /> 23. Tu X, Wang CC (2004) The involvement cdc2-related kinases (CRKs)                        Characterization novel alanine-rich protein located surface microdomains <br />     Trypanosoma brucei cell-cycle regulation distinctive stage-specific                       Trypanosoma brucei. J Biol Chem 275: 4072&#226;&#8364;&#8220;4080. <br />     phenotypes caused CRK3 depletion. J Biol Chem 279: 20519&#226;&#8364;&#8220;20528.                            49. Morgan GW, Allen CL, Jeffries TR, Hollinshead M, Field MC (2001) <br /> 24. Badjatia N, Ambrosio DL, Lee JH, Gunzl A (2013) Trypanosome cdc2-related                          Developmental morphological regulation clathrin-mediated endocytosis <br />     kinase 9 controls spliced leader RNA cap4 methylation phosphorylation                      Trypanosoma brucei. J Cell Sci 114: 2605&#226;&#8364;&#8220;2615. <br />     RNA polymerase II subunit RPB1. Mol Cell Biol In press.                                   50. Field MC, Allen CL, Dhir V, Goulding D, Hall BS, et al. (2004) New <br /> 25. Tu X, Wang CC (2005) Coupling posterior cytoskeletal morphogenesis                      approaches microscopic imaging Trypanosoma brucei. Microsc Microanal <br />     G1/S transition Trypanosoma brucei cell cycle. Mol Biol Cell 16: 97&#226;&#8364;&#8220;105.                   10: 621&#226;&#8364;&#8220;636. S1431927604040942 [pii];10.1017/S1431927604040942 [doi]. <br /> 26. Van Hellemond JJ, Neuville P, Schwartz RJ, Matthews KR, Mottram JC (2000)                     51. May SF, Peacock L, Almeida Costa CI, Gibson WC, Tetley L, et al. (2012) The <br />     Isolation Trypanosoma brucei CYC2 CYC3 cyclin genes rescue yeast                   Trypanosoma brucei AIR9-like protein cytoskeleton-associated required for <br />     G1 cyclin mutant. Functional characterisation CYC2. J Biol Chem 275: 8315&#226;&#8364;&#8220;                     nucleus positioning accurate cleavage furrow placement. Mol Microbiol. <br />     8323.                                                                                             10.1111/j.1365-2958.2012.08008.x [doi]. <br />  <br />  <br />  <br /> PLOS ONE | www.plosone.org                                                                   14                                    June 2013 | Volume 8 | Issue 6 | e67327 <br />                                                                                                                                 Characterisation CRK12:CYC9 T. brucei <br />  <br />  <br /> 52. Gopinathan <br /> </body></html>